Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$655M |
| 2 |
Coty
COTY
|
+$380M |
| 3 |
ConocoPhillips
COP
|
+$250M |
| 4 |
Zimmer Biomet
ZBH
|
+$213M |
| 5 |
Valero Energy
VLO
|
+$170M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$523M |
| 2 |
Merck
MRK
|
+$375M |
| 3 |
SHPG
Shire pic
SHPG
|
+$362M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$310M |
| 5 |
CELG
Celgene Corp
CELG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.57% |
| 2 | Technology | 12.05% |
| 3 | Financials | 10.74% |
| 4 | Consumer Discretionary | 9.44% |
| 5 | Energy | 8.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EMKR
2726
DELISTED
Emcore Corp
EMKR
| $1.21M | ﹤0.01% |
33,057
+7,607
| +30% | +$324K |
|
|
BSTC
2727
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $1.2M | ﹤0.01% |
19,300
-1,689
| -8% | -$112K |
|
2728
The RMR Group
RMR
$336M
| $1.2M | ﹤0.01% |
+19,660
| New | +$1.3M |
|
|
HARP
2729
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $1.2M | ﹤0.01% |
+12,666
| New | +$1.66M |
|
2730
Regional Management Corp
RM
$308M
| $1.2M | ﹤0.01% |
49,011
-34,286
| -41% | -$913K |
|
2731
Alamos Gold
AGI
$16.3B
| $1.2M | ﹤0.01% |
235,229
-789,020
| -77% | -$3.6M |
|
|
ACBI
2732
DELISTED
Atlantic Capital Bancshares, Inc. Common Stock
ACBI
| $1.19M | ﹤0.01% |
66,923
-376,111
| -85% | -$6.94M |
|
|
HAYN
2733
DELISTED
Haynes International, Inc.
HAYN
| $1.19M | ﹤0.01% |
36,243
+3,458
| +11% | +$112K |
|
|
SBBP
2734
DELISTED
Strongbridge Biopharma plc.
SBBP
| $1.18M | ﹤0.01% |
237,776
+74,791
| +46% | +$368K |
|
2735
Pool Corp
POOL
$6.77B
| $1.18M | ﹤0.01% |
7,168
+1,197
| +20% | +$186K |
|
2736
Crocs
CROX
$5.89B
| $1.18M | ﹤0.01% |
45,891
-701,998
| -94% | -$19.2M |
|
2737
CALL
Medpace
MEDP
$17.1B
| $1.18M | ﹤0.01% |
20,000
+10,000
| +100% | +$597K |
|
2738
CALL
Glaukos
GKOS
$10.7B
| $1.18M | ﹤0.01% |
15,000
+10,000
| +200% | +$668K |
|
2739
PUT
Ares Capital
ARCC
$14.3B
| $1.17M | ﹤0.01% |
+68,500
| New | +$1.15M |
|
2740
Blackrock
BLK
$182B
| $1.17M | ﹤0.01% |
2,745
-118,159
| -98% | -$49.6M |
|
2741
Marker Therapeutics
MRKR
$25.3M
| $1.17M | ﹤0.01% |
+17,758
| New | +$1.04M |
|
2742
IDT Corp
IDT
$1.73B
| $1.17M | ﹤0.01% |
176,386
+58,929
| +50% | +$393K |
|
2743
PUT
Walmart Inc
WMT
$839B
| $1.17M | ﹤0.01% |
+36,000
| New | +$1.17M |
|
2744
iShares MSCI Qatar ETF
QAT
$59.4M
| $1.17M | ﹤0.01% |
62,960
+21,688
| +53% | +$404K |
|
2745
Vanguard FTSE All-World ex-US ETF
VEU
$71B
| $1.16M | ﹤0.01% |
23,197
-10,306
| -31% | -$505K |
|
|
MFNC
2746
DELISTED
Mackinac Financial Corporation
MFNC
| $1.16M | ﹤0.01% |
+73,902
| New | +$1.14M |
|
2747
MaxLinear
MXL
$6.02B
| $1.16M | ﹤0.01% |
+45,492
| New | +$995K |
|
|
CYBE
2748
DELISTED
Cyberoptics Corp
CYBE
| $1.16M | ﹤0.01% |
67,903
+23,676
| +54% | +$469K |
|
|
PHAS
2749
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $1.16M | ﹤0.01% |
121,979
-11,043
| -8% | -$43.7K |
|
2750
AutoZone
AZO
$49.4B
| $1.16M | ﹤0.01% |
1,130
-211,062
| -99% | -$189M |
|
Similar funds
Israel Englander's Q1 2019 Portfolio in Review
As of Q1 2019, Israel Englander held 4,608 positions worth $66.8B, up 4.2% from $64.1B the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.
Israel Englander withdrew a net $6.14B in Q1 2019, closing 675 positions and reducing 1,467 holdings. Its most notable exit was Merck, an estimated $375M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 14% a quarter earlier, followed by Technology and Financials.
Against the trend, Israel Englander opened a new position in Zimmer Biomet worth $232M.
- Israel Englander's largest Q1 2019 buy was Zimmer Biomet: 1,870,503 shares worth $232M.
- Israel Englander added most to Walt Disney in Q1 2019, an estimated $655M increase.
- Israel Englander's biggest Q1 2019 reduction was Apple, cutting an estimated $523M.
- Israel Englander fully exited Merck in Q1 2019, selling an estimated $375M.
- Israel Englander's ten largest holdings make up 7.1% of its $66.8B portfolio in Q1 2019.
- Israel Englander opened 914 new positions and closed 675 in Q1 2019.
- Israel Englander's portfolio value rose 4.2% quarter-over-quarter to $66.8B.
Based on Millennium Management's 13F filing for Q1 2019, filed 14 May 2019.